Vertex PharmaceuticalsVRTX
VRTX
0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 10 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
24% more first-time investments, than exits
New positions opened: 189 | Existing positions closed: 153
11% more call options, than puts
Call options by funds: $780M | Put options by funds: $700M
0% less funds holding
Funds holding: 1,527 [Q3] → 1,526 (-1) [Q4]
0.67% less ownership
Funds ownership: 92.25% [Q3] → 91.57% (-0.67%) [Q4]
9% less repeat investments, than reductions
Existing positions increased: 547 | Existing positions reduced: 603
14% less capital invested
Capital invested by funds: $110B [Q3] → $95.5B (-$15B) [Q4]
45% less funds holding in top 10
Funds holding in top 10: 29 [Q3] → 16 (-13) [Q4]
Research analyst outlook
10 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$408
17%
downside
Avg. target
$475
4%
downside
High target
$550
12%
upside
10 analyst ratings
4 positive
40%
6 neutral
60%
0 negative
0%
RBC Capital Brian Abrahams 17% 1-year accuracy 12 / 69 met price target | 17%downside $408 | Sector Perform Maintained | 20 Feb 2025 |
Canaccord Genuity Whitney Ijem 28% 1-year accuracy 12 / 43 met price target | 14%downside $424 | Hold Upgraded | 12 Feb 2025 |
Truist Securities Joon Lee 53% 1-year accuracy 21 / 40 met price target | 6%upside $520 | Buy Maintained | 11 Feb 2025 |
Scotiabank Greg Harrison 49% 1-year accuracy 19 / 39 met price target | 9%downside $450 | Sector Perform Maintained | 11 Feb 2025 |
Cantor Fitzgerald Olivia Brayer 68% 1-year accuracy 13 / 19 met price target | 3%downside $480 | Overweight Reiterated | 11 Feb 2025 |
Financial journalist opinion
Based on 31 articles about VRTX published over the past 30 days
Neutral
Business Wire
2 days ago
Vertex Announces Program Updates for Type 1 Diabetes Portfolio
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several updates on the Company's type 1 diabetes (T1D) portfolio. VX-264 Update Vertex has completed enrollment and dosing in Parts A and B of the Phase 1/2 VX-264 (cells + device) study and the planned analysis at Day 90 for Part B. In Part B of the study, participants received the full dose of the investigational fully differentiated pancreatic islet cell therapy encapsulated in a proprietary immunopro.
Negative
The Motley Fool
2 days ago
Rattled by the Stock Market Sell-Off? These 3 Stocks Outperformed the S&P 500 During the Great Recession
The economy has been on shaky ground for a while, and President Trump's tariffs and trade wars could finally send it into a recession. That's a big concern for the market these days as consumers have been keeping discretionary spending to a minimum as high costs have created many affordability issues.
Neutral
Zacks Investment Research
3 days ago
Vertex Pharmaceuticals (VRTX) Advances While Market Declines: Some Information for Investors
Vertex Pharmaceuticals (VRTX) closed at $502.55 in the latest trading session, marking a +0.45% move from the prior day.
Neutral
CNBC Television
3 days ago
Final Trades: Vertex Pharma, Netflix and the IYF
The Investment Committee give you their stop stocks to watch for the second half.
Negative
Proactive Investors
3 days ago
Biopharma firms with foreign exposure face disruption as Trump's tariffs loom
The biopharmaceutical industry is bracing for potential disruptions from proposed tariffs aimed at encouraging companies to move manufacturing operations back to the United States. This week, president Donald Trump suggested that tariffs could be implemented on pharma products made outside the US, with a particular focus on Ireland, where many biopharma companies benefit from favorable tax conditions.
Negative
Market Watch
3 days ago
Trump Weighs Tariffs on Ireland's Pharma Industry. How to Play the Sector.
Biopharmaceutical stocks are having their time in the spotlight thanks to President Donald Trump, who vowed to take aim at Ireland's status as a pharma hub with new tariffs. Analysts at Jefferies JEF-8.32% say there is a smart way to play the sector.
Positive
CNBC Television
6 days ago
Trade Tracker: Steve Weiss buys Vertex Pharmaceuticals
Steve Weiss, Founder and Managing Partner of Short Hills Capital Partners joins CNBC's “Halftime Report” to explain why he's buying the Pharmaceutical company
Negative
Zacks Investment Research
1 week ago
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know
The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $503.20, representing a -1.37% change from its previous close.
Neutral
Zacks Investment Research
1 week ago
Market Pullback After a Historic Rally: What Investors Should Do Now
Instead of blindly buying during a selloff, Jeremy Mullin offers a four-step plan for 2025 to help investors pinpoint stocks and industries that will lead the next leg higher. Learn how to develop a disciplined strategy to capitalize on the market's abundant opportunities.
Positive
Investors Business Daily
1 week ago
As The Biotech Sector Remains Strong, Vertex Stock Trades Near Buy Point
Biotech stocks are among the few industry groups producing breakouts and buyable stocks in an uncertain market. Vertex stock is among top biotechs to watch.
Charts implemented using Lightweight Charts™